isosorbide mononitrate
Summary
Isosorbide mononitrate is a long-acting oral organic nitrate used for chronic stable angina prophylaxis. It is a prodrug-independent NO donor that causes venodilation (↓preload) and, at higher doses, arteriolar dilation, reducing myocardial O2 demand. Contraindicated with PDE-5 inhibitors (risk of severe hypotension); nitrate-free interval is needed to prevent tolerance.
Detail
**Class/Mechanism:** Organic nitrate (vasodilator). Metabolized in vascular smooth muscle to nitric oxide (NO) → activates guanylate cyclase → ↑cGMP → ↓intracellular Ca2+ and dephosphorylation of myosin light chain → smooth muscle relaxation. Predominantly venodilation (↓preload, ↓LV wall tension, ↓myocardial O2 demand); at higher doses also dilates arterioles (↓afterload) and epicardial coronary arteries (relieves vasospasm, e.g., Prinzmetal angina).
**Pharmacokinetics:** Active metabolite of isosorbide dinitrate, so it has no first-pass hepatic metabolism. ~100% oral bioavailability and a longer half-life (~4-5 h) than isosorbide dinitrate or nitroglycerin. It is dosed once daily (extended-release) or BID (asymmetric dosing, e.g., 8 AM and 3 PM). It is NOT used for acute angina attacks because onset is too slow. Use sublingual nitroglycerin for acute attacks.
**Clinical uses:** Chronic stable angina prophylaxis (reduces frequency of attacks; no proven mortality benefit). Vasospastic angina. Isosorbide dinitrate + hydralazine is used in HFrEF, with proven mortality benefit in self-identified African American patients (A-HeFT). Nitrates do not improve survival in CAD.
**Adverse effects:** Headache (meningeal vessel dilation; the most common), flushing, orthostatic hypotension, reflex tachycardia (often combined with β-blocker to blunt this), dizziness. Methemoglobinemia is rare (more with other nitrates/nitrites).
**Tolerance:** Continuous exposure leads to tolerance (depleted sulfhydryl groups, neurohormonal activation, ↑oxidative stress). Prevent with a nitrate-free interval of 8-12 h (usually overnight).
**Contraindications/interactions:** - PDE-5 inhibitors (sildenafil, tadalafil, vardenafil): both ↑cGMP, causing profound hypotension. Avoid within 24 h of sildenafil/vardenafil and 48 h of tadalafil. - Riociguat (sGC stimulator). - Caution with hypertrophic obstructive cardiomyopathy, severe aortic stenosis, right ventricular infarct (preload dependent), and increased intracranial pressure.
**Board pearls:** - Nitrates + β-blockers: the β-blocker counteracts reflex tachycardia, and nitrates counteract the β-blocker's increase in end-diastolic volume. - Nitrates ↓ preload, so they ↓ end-diastolic volume and ↓ wall tension (law of Laplace), reducing O2 demand. - Compared with nitroglycerin: nitroglycerin is used for acute attacks (sublingual) and IV for ACS/hypertensive emergency/acute HF. Isosorbide mononitrate and dinitrate are used for chronic prophylaxis. - Nitroprusside is a different drug (NO donor for hypertensive emergency; risk of cyanide toxicity).
Sources
- First Aid for the USMLE Step 1 (Cardiovascular Pharmacology: Antianginal therapy)
- Katzung's Basic & Clinical Pharmacology (Vasodilators and the Treatment of Angina Pectoris)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- 2021 AHA/ACC Chest Pain Guideline and 2023 AHA/ACC Chronic Coronary Disease Guideline
- A-HeFT trial (Taylor et al., NEJM 2004)
- Pathoma / Sketchy Pharm (Antianginals)
Reviewed by Medusa editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.